Since the COVID-19 pandemic, pharma companies have reduced their investments in traditional in-person engagements with HCPs. However, if DTC ads face restrictions under Robert F. Kennedy Jr.’s term as the Secretary of the Department of Health and Human Services, there may need to be a reinforced effort on HCP marketing. In Medical Marketing + Media (MM+M), Sonam Dubey details how a potential DTC advertising ban would impact pharma companies and how they can proactively prepare for possible ad restrictions.
